{"changeSha256":"34ea2adb26534c62a13ed98267d82275d55e91b399a0c3d461d59c57e6209b31","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Somatuline Depot and other lanreotide products","before":"U.S. label record","field":"Status"},{"after":"A somatostatin analogue first approved by FDA as Somatuline Depot in 2007. The cited label covers acromegaly, certain neuroendocrine tumors and carcinoid syndrome.","before":"A somatostatin analogue. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"Smaller randomized, placebo-controlled trials described in the label support its uses, including a tumor trial in which lanreotide lengthened progression-free survival. The cited label has no boxed warning.","before":"The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"Lanreotide acetate, Somatuline Depot","before":"Lanreotide acetate","field":"Related names"},{"after":"dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be, fda-drugs-nda215395-2021-12-17-2de401fe75fc, fda-drugs-anda217193-2024-05-21-688e02d085c4","before":"dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3]; U.S. Food and Drug Administration [sources: fda-drugs-nda022074-2007-08-30-439ff00e36be]","before":"U.S. National Library of Medicine [sources: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3]","field":"Named organizations"},{"after":"name: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; aliases: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be; category: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; status: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be, fda-drugs-nda215395-2021-12-17-2de401fe75fc, fda-drugs-anda217193-2024-05-21-688e02d085c4; summary: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be; evidenceNote: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3","before":"name: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; aliases: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; category: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; status: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; summary: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; evidenceNote: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/lanreotide/versions/3/","version":3},"id":"profile:lanreotide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the generic lanreotide label, and added Drugs@FDA approval records for lanreotide products.","peptideSlugs":["lanreotide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/lanreotide/v2.json","sha256":"e2bf8b36d027aa01edfd6773359e7f1dc7aa8270ef4aac2ae9427d6d315462d0"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/lanreotide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"Lanreotide acetate injection · SPL version 3 · published 2025-06-02","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=2892b4c3-0329-4d29-97ff-3b45283bbab1&version=3","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda022074-2007-08-30-439ff00e36be","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022074%22&limit=1","verifiedAt":"2026-08-14"}],"subject":{"slug":"lanreotide","type":"profile"}}
